298380 — ABL Bio Income Statement
0.000.00%
Last trade - 00:00
- KR₩1tn
- KR₩1tn
- KR₩66bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,989 | 8,104 | 5,332 | 67,301 | 65,547 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 37,850 | 67,751 | 57,637 | 63,801 | 68,164 |
Operating Profit | -33,861 | -59,647 | -52,305 | 3,500 | -2,617 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30,191 | -55,606 | -43,558 | 3,209 | -2,647 |
Provision for Income Taxes | |||||
Net Income After Taxes | -30,191 | -55,606 | -43,558 | 3,209 | -2,647 |
Net Income Before Extraordinary Items | |||||
Net Income | -30,191 | -55,606 | -43,558 | 3,209 | -2,647 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -30,191 | -55,606 | -43,558 | 3,209 | -2,647 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -667 | -1,207 | -927 | 12 | -55.3 |
Dividends per Share |